Subscribe to our Newsletters !!

    Kumar Jeetendra

    Minitsry of Health rules against incorporating Itolizumab in clinical administration convention for COVID-19

    The National Task Force on COVID-19 has ruled against incorporating Itolizumab medicate in clinical administration conventions for rewarding the malady despite the fact that the DCGI has affirmed its “confined crisis use” in contaminated patients, official sources said. Considering the neglected clinical needs in COVID-19, Itolizumab, a previously endorsed medication of Biocon, utilized for rewarding

    Analysts recognize anticoagulation operator that stifles SARS-CoV-2 replication in vitro

    Effective antivirals with secure clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients using COVID-19, the authors discovered that hypercoagulability according to elevated levels of D-dimers was associated with illness severity. By calculating of a U.S. FDA approved drug library, the authors identified

    Nitric oxide treatment can be essential in the battle against COVID-19

    Nitric oxide therapy could be critical in the world’s struggle against SARS-CoV-2, the coronavirus which causes COVID-19, according to a review by the George Washington University (GW). Nitric oxide is an antimicrobial and anti inflammatory molecule with key roles in pulmonary arterial role in the context of viral infections as well as other pulmonary diseases.

    WHO says COVID-19 pandemic is ‘one major wave’, not occasional

    The World Health Organization on Tuesday warned against complacency about new coronavirus transmission at the northern hemisphere summer, stating that this virus did not act like influenza that tended to follow seasonal trends. “Folks are still thinking about seasons. What we all need to get our heads around is this is a new virus and.

    Artificial Intelligence detects Prostate Cancer With Near-Perfect Accuracy

    A study in the University of Pittsburgh shows the highest accuracy thus far in understanding and characterizing prostate cancer using an artificial intelligence (AI) application.1 “Humans are great at recognizing anomalies, but they have their particular biases or previous experience,” says senior writer Rajiv Dhir, MD, MBA, chief pathologist and vice chair of pathology at

    Roche’s Tocilizumab neglects to meet essential end focuses for COVID-19 related pneumonia

    Swiss Drug maker Roche on July 29 declared that its drug Actemra (Tocilizumab), which has emerged as a widely prescribed drug for treating hosiptalised COVID-19 patients, didn’t fulfill its primary endpoint of improved clinical standing in hospitalised adult patients with acute COVID-19 related pneumonia. In addition, the primary secondary endpoint of decreased patient mortality week